A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology

5Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Non-invasive, immuno-dynamic, biomarkers positioned in cancer patient’s blood milieu with immuno-oncological applications are rare. We recently established a “first-in-class” serum functional immunodynamics status (sFIS) assay, wherein in vitro assessment of serum-induced myeloid NFkB and/or interferon (IFN) response-signaling can be performed to “mimic” in situ patient’s serum immune-biology. This modality has clear implications for anticipating patient prognosis and immunotherapy-relevant stratification.

Cite

CITATION STYLE

APA

Sprooten, J., Coosemans, A., & Garg, A. D. (2022). A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology. OncoImmunology, 11(1). https://doi.org/10.1080/2162402X.2021.2024692

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free